Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Diphenhydramine
Drug ID BADD_D00686
Description Diphenhydramine - perhaps known most commonly as its brand name formulation Benadryl - is a first-generation H1 receptor antihistamine that is used extensively for the treatment of seasonal allergies, insect bites and stings, and rashes [L5263, L5266, L5269, F3379]. However, it also has antiemetic, antitussive, hypnotic, and antiparkinson properties [L5269, F3352]. As histamine receptors exist both peripherally and in the central nervous system, diphenhydramine has been shown to cause sedation due to its competitive antagonism of histamine H1 receptors within the central nervous system [L5263, L5266, L5269, F3379, A174541]. While its use in allergy therapy can sometimes fall out of favor due to its sedative effect, diphenhydramine has been repurposed for use within many non-prescription over-the-counter sleep aids and cough-and-cold medications that have been marketed for "night time" use [L5263, L5281, L5287]. Diphenhydramine is also used in combination with [DB14132] as the anti-nausea drug [DB00985] where it is utilized primarily for its antagonism of H1 histamine receptors within the vestibular system [A1540]. Diphenhydramine has also been shown to be implicated in a number of neurotransmitter systems that affect behaviour including dopamine, norepinephrine, serotonin, acetylcholine, and opioid [A1539]. As a result, diphenhydramine is being investigated for its anxiolytic and anti-depressant properties.
Indications and Usage Diphenhydramine is a first-generation histamine H1 receptor antagonist (H1 antihistamine) that is widely available as a non-prescription, over-the-counter (OTC) medication. As an OTC medication, diphenhydramine is typically formulated as tablets and creams indicated for use in treating sneezing, runny nose, itchy/watery eyes, itching of nose or throat, insomnia, pruritis, urticaria, insect bites/stings, allergic rashes, and nausea [L5263, L5266, L5269, F3379, A174541]. Additionally, when the use of oral diphenhydramine is impractical, there are also prescription-only formulations such as diphenhydramine injection products that are effective in adults and pediatric patients (other than premature infants and neonates) for: i) the amelioration of allergic reactions to blood or plasma, in anaphylaxis as an adjunct to epinephrine and other standard measures after acute allergic reaction symptoms have been controlled, and for other uncomplicated allergic conditions of the immediate type when oral therapy is impossible or contraindicated [F3352]; ii) the active treatment of motion sickness [F3352]; and iii) use in parkinsonism when oral therapy is impossible or contraindicated, as follows: parkinsonism in the elderly who are unable to tolerate more potent agents; mild cases of parkinsonism in other age groups, and in other cases of parkinsonism in combination with centrally acting anticholinergic agents [F3352].
Marketing Status approved; investigational
ATC Code D04AA32; R06AA02
DrugBank ID DB01075
KEGG ID D00300
MeSH ID D004155
PubChem ID 3100
TTD Drug ID D01FGR
NDC Product Code 76168-065; 52119-012; 73281-001; 0031-9304; 82179-003
UNII 8GTS82S83M
Synonyms Diphenhydramine | Benzhydramine | Diphenylhydramine | Diphenylhydramin | 2-Diphenylmethoxy-N,N-dimethylethylamine | Benhydramin | Benadryl | Benylin | Diphenhydramine Citrate | Citrate, Diphenhydramine | Diphenhydramine Citrate (1:1) | Diphenhydramine Hydrochloride | Hydrochloride, Diphenhydramine | Dormin | Allerdryl | Dimedrol
Chemical Information
Molecular Formula C17H21NO
CAS Registry Number 58-73-1
SMILES CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Musculoskeletal pain15.03.04.0070.000201%
Mydriasis17.02.11.003; 06.05.03.0040.003425%Not Available
Myocardial ischaemia02.02.02.008; 24.04.04.0100.000537%Not Available
Myoclonus17.02.05.0080.000470%Not Available
Nasal congestion22.04.04.0010.000430%
Nausea07.01.07.001--
Neck pain15.03.04.0090.000403%
Neoplasm malignant16.16.01.001--Not Available
Nervousness19.06.02.0030.000658%Not Available
Neuritis17.09.03.001--Not Available
Neuropathy peripheral17.09.03.003--Not Available
Nightmare19.02.03.003--Not Available
Nystagmus06.05.02.006; 17.02.02.0060.000940%
Ocular hyperaemia06.04.05.004--Not Available
Oedema14.05.06.010; 08.01.07.006--Not Available
Oedema peripheral14.05.06.011; 08.01.07.007; 02.05.04.007--
Oliguria20.01.03.0040.000134%Not Available
Pain08.01.08.004--
Pain of skin23.03.03.003--
Palpitations02.11.04.012--
Panic attack19.06.04.001--Not Available
Paraesthesia23.03.03.094; 17.02.06.005--
Pharyngeal oedema22.04.05.003; 23.04.01.016; 10.01.05.0160.000631%Not Available
Photosensitivity reaction23.03.09.003--
Pollakiuria20.02.02.007--
Polydipsia14.05.02.001; 05.03.03.0020.000564%Not Available
Pressure of speech19.19.03.0060.000134%Not Available
Productive cough22.02.03.005--
Protrusion tongue17.02.05.037; 07.14.02.0020.000134%Not Available
Pruritus23.03.12.0010.012357%
The 7th Page    First    Pre   7 8 9 10 11    Next   Last    Total 13 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene